Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,012 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Radiation Therapy (RT) Clear all
Completed Phase 3 Interventional Results available

An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

NCT02667587
View directory record Official record
Conditions
Brain Neoplasms
Interventions
Nivolumab, Temozolomide, Radiotherapy, Nivolumab Placebo
Drug · Radiation · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Nov 15, 2026, 12:10 PM EST
Terminated Not applicable Interventional Results available

Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases

NCT02336763
View directory record Official record
Conditions
Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Stage IIA Uveal Melanoma, Stage IIB Uveal Melanoma, Stage IIIA Uveal Melanoma, Stage IIIB Uveal Melanoma, Stage IIIC Uveal Melanoma
Interventions
External Beam Radiation Therapy, Laboratory Biomarker Analysis
Radiation · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Nov 15, 2026, 12:10 PM EST
Recruiting Phase 2 Interventional

Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma

NCT04594187
View directory record Official record
Conditions
Melanoma
Interventions
Immunotherapy, Quality-of-Life Assessment, Radiation Therapy
Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Jacksonville, Florida • Camden, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 15, 2026, 12:10 PM EST
Recruiting Phase 3 Interventional

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

NCT07578116
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma, Oligometastatic Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment, Computed Tomography, Cyclin-Dependent Kinase 4 Inhibitor, Cyclin-Dependent Kinase 6 Inhibitor, Echocardiography Test, HER2-targeted Therapy, Hormone Therapy, Magnetic Resonance Imaging, Mammography, Pertuzumab, Positron Emission Tomography, Radiation Boost, Radiation Therapy, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Taxane Compound, Total Mastectomy, Trastuzumab, Trastuzumab Deruxtecan, Trastuzumab Emtansine, Ultrasound Imaging
Procedure · Drug · Biological + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2033
U.S. locations
59
States / cities
Jonesboro, Arkansas • Derby, Connecticut • Fairfield, Connecticut + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 15, 2026, 12:10 PM EST
Recruiting Phase 1Phase 2 Interventional

Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies

NCT05039632
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Solid Neoplasm
Interventions
Hafnium Oxide-containing Nanoparticles NBTXR3, Radiation Therapy
Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Nov 15, 2026, 12:10 PM EST
Completed Phase 2 Interventional

Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00274833
View directory record Official record
Conditions
CNS Tumor, Adult
Interventions
erlotinib hydrochloride, temozolomide, radiation therapy
Drug · Radiation
Lead sponsor
David Peereboom
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Nov 15, 2026, 12:10 PM EST
Completed Phase 3 Interventional Results available

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

NCT01546987
View directory record Official record
Conditions
Prostate Cancer
Interventions
GnRH agonist, Anti-androgen, TAK-700, Radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
165
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 136 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Nov 15, 2026, 12:10 PM EST
Recruiting Phase 1Phase 2 Interventional

Proton or Photon RT for Retroperitoneal Sarcomas

NCT01659203
View directory record Official record
Conditions
Retroperitoneal Sarcoma
Interventions
IG-IMPT, IG IMRT
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
10
States / cities
Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 15, 2026, 12:10 PM EST
Completed Phase 2 Interventional Results available

S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction

NCT00086996
View directory record Official record
Conditions
Esophageal Cancer
Interventions
fluorouracil, oxaliplatin, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
143
States / cities
Mobile, Alabama • Anchorage, Alaska • Bentonville, Arkansas + 92 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2013 · Synced Nov 15, 2026, 12:10 PM EST
Completed Not applicable Interventional Results available

Same-session MR-only Simulation and Treatment With MRI-guided Adaptive Palliative RadioTherapy

NCT03824366
View directory record Official record
Conditions
Malignancy, Metastasis, Hemoptysis, Gastrointestinal Bleeding, Pelvic Bleeding, Superior Vena Cava Syndrome, Mediastinal Disease
Interventions
Volumetric MR imaging, Radiation therapy
Device · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Nov 15, 2026, 12:10 PM EST
Recruiting Phase 2 Interventional

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

NCT07281417
View directory record Official record
Conditions
Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8, Stage IVA Sinonasal Cancer AJCC v8, Stage IVB Sinonasal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Carboplatin, Cemiplimab, Chemoradiotherapy, Cisplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Positron Emission Tomography, Radiation Therapy, Surgical Procedure
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
18
States / cities
Irvine, California • Los Angeles, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 15, 2026, 12:10 PM EST
Active, not recruiting Phase 1Phase 2 Interventional Results available

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT01386385
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma, Minimally Invasive Lung Adenocarcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions
3-Dimensional Conformal Radiation Therapy, Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Placebo Administration, Veliparib
Radiation · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
232
States / cities
Anchorage, Alaska • Tucson, Arizona • Beverly Hills, California + 158 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2026 · Synced Nov 15, 2026, 12:10 PM EST
Active, not recruiting Phase 3 Interventional

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

NCT04557059
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Radiotherapy, LHRHa, Apalutamide
Radiation · Drug
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Industry
Eligibility
18 Years and older · Male only
Enrollment
691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
13
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 12:10 PM EST
Terminated Phase 3 Interventional Results available

Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer

NCT00004859
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, thalidomide, radiation therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
235
States / cities
Fort Smith, Arkansas • Modesto, California • Salinas, California + 168 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Nov 15, 2026, 12:10 PM EST
Completed Not applicable Interventional Results available

4D Image-Guided Partial Breast Radiation in Stage 0 and l Breast Cancer

NCT01646346
View directory record Official record
Conditions
Breast Cancer
Interventions
4D Conformal Image-Guided Partial Breast RT
Radiation
Lead sponsor
Yale University
Other
Eligibility
50 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 23, 2018 · Synced Nov 15, 2026, 12:10 PM EST
Terminated Not applicable Interventional Results available

Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery

NCT01958580
View directory record Official record
Conditions
Stage IA Uterine Sarcoma, Stage IB Uterine Sarcoma, Stage IC Uterine Sarcoma, Stage IIA Uterine Sarcoma, Stage IIB Uterine Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Corpus Leiomyosarcoma
Interventions
Gemcitabine Hydrochloride, Docetaxel, Internal Radiation Therapy, Intensity-Modulated Radiation Therapy, External Beam Radiation Therapy, Laboratory Biomarker Analysis
Drug · Radiation · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2023 · Synced Nov 15, 2026, 12:10 PM EST
Suspended Phase 2Phase 3 Interventional

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

NCT04402788
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma
Interventions
Atezolizumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy
Drug · Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
411
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 296 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2026 · Synced Nov 15, 2026, 12:10 PM EST
Not yet recruiting Not applicable Interventional

Removing the Planning Tumor Volume From Radiation Therapy for the Treatment of Head and Neck Squamous Cell Carcinoma

NCT07926906
View directory record Official record
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Stage 0 Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage I Hypopharyngeal Carcinoma AJCC v8, Stage I Laryngeal Cancer AJCC v8, Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage II Hypopharyngeal Carcinoma AJCC v8, Stage II Laryngeal Cancer AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Chemotherapy, Computed Tomography, Endoscopic Procedure, FDG-Positron Emission Tomography and Computed Tomography Scan, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Survey Administration
Drug · Procedure · Radiation + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 15, 2026, 12:10 PM EST
Recruiting Phase 3 Interventional

Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma

NCT07452458
View directory record Official record
Conditions
Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Questionnaire Administration, Radiation Therapy, Temozolomide, Temporally-modulated Pulsed Radiation Therapy
Procedure · Other · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
54
States / cities
Irvine, California • Los Angeles, California • Orange, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Nov 15, 2026, 12:10 PM EST
Active, not recruiting Phase 3 Interventional

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

NCT04513717
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Apalutamide, Bicalutamide, Biospecimen Collection, Bone Scan, Buserelin, Computed Tomography, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Magnetic Resonance Elastography, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Relugolix, Triptorelin
Drug · Procedure · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
2,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2038
U.S. locations
594
States / cities
Fairbanks, Alaska • Gilbert, Arizona • Peoria, Arizona + 438 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Nov 15, 2026, 12:10 PM EST
Completed Phase 1 Interventional

Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer

NCT01899989
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT), cisplatin or carboplatin-based
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Nov 15, 2026, 12:10 PM EST
Completed Phase 3 Interventional Results available

Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer

NCT00047008
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin, Standard fractionation RT, Accelerated fractionation radiation therapy, Conventional surgery for select patients
Drug · Radiation · Procedure
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2022
U.S. locations
195
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Nov 15, 2026, 12:10 PM EST
Completed Phase 1Phase 2 Interventional Results available

Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00280150
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, carboplatin, erlotinib hydrochloride, paclitaxel, 3-dimensional conformal radiation therapy
Biological · Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Concord, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Nov 15, 2026, 12:10 PM EST
Completed Phase 1 Interventional

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

NCT03423628
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)
Interventions
Radiation Therapy, AZD1390
Radiation · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 15, 2026, 12:10 PM EST